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Abstract
Blood transfusion has been used to treat the injured since the US
Civil War. Now, it saves the lives of tens of thousands of injured
patients each year. However, not everyone who receives blood
benefits, and some recipients are injured by the transfusion itself.
Effective blood therapy in trauma management requires an
integration of information from diverse sources, including data
relating to trauma and blood use epidemiology, medical systems
management, and clinical care. Issues of current clinical concern in
highly developed trauma systems include how to manage massive
transfusion events, how to limit blood use and so minimize
exposure to transfusion risks, how to integrate new hemorrhage
control modalities, and how to deal with blood shortages. Less
developed trauma systems are primarily concerned with speeding
transport to specialized facilities and assembling trauma center
resources. This article reviews the factors that effect blood use in
urgent trauma care.
Introduction
Injury is common. Across the world, motor vehicle accidents
are the most common cause of severe injury [1] and the World
Health Organization estimates that by 2020 vehicular injury will
be the second most common cause of mortality and morbidity
worldwide [2]. In the USA almost 100,000 people die each
year from traumatic injury, about half of whom die before they
reach any medical care [3,4]. Of the one in seven Americans
who are injured each year two-thirds seek medical care, and
about 10% of those who seek care are admitted to a hospital,
amounting to about 2.7 million admissions each year [5]. Such
admissions range from otherwise healthy pregnant women who
undergo a short course of fetal monitoring after a fall or seatbelt
injury to the profoundly injured.
Hemorrhage is the second most common cause of death
among the injured [4,6,7]. The extent of hemorrhage in any
given case is a function of the degree of vascular disruption,
blood pressure at the site of the injury, and time between
injury and definitive care. Once reaching care, about 10% of
trauma care patients receive blood. For example, 514
patients received blood products among a total of 5623
patients presenting directly from the scene of injury to the
University of Maryland Shock Trauma Center in the calendar
year 2000 [8]. Three-quarters of all of the red blood cells
(RBCs) used in the Center were given to just 147 patients,
who each received more than 10 units; and 50% of all RBCs
went to 68 patients, who received more than 20 units each.
Aggregate survival rates in these groups were 61% and
50%, respectively, with the average age of survivors being 35
years. The saving of years of potentially productive life was
therefore proportionally great.
Patterns of blood use
Patterns of blood use in trauma care can appear to be quite
arbitrary when only small numbers of units of RBCs are given.
During the Vietnam War, a US Army group that used saline for
primary resuscitation reported that 16% of all patients were
transfused, whereas a US Navy group that used whole blood
for primary resuscitation reported that 36% of all casualties
were transfused [9,10]. More recently, Gould and coworkers
[11] reported that 50% of patients who received blood in level
1 trauma centers in Illinois received only 1 or 2 units of RBCs.
However, Como and colleagues [8] described an academic
center testing hypotensive resuscitation in which fewer than
25% of all transfused patients received only 1 or 2 units of
RBCs. Even this number is artificially increased in the sense
that some patients who do not benefit from blood still receive 1
or 2 units in order to preserve their organs for transplantation.
Massive transfusion, commonly defined as more than 10 units
of RBC in 24 hours, is a special aspect of trauma injury blood
use, involves the most severely injured patients, and absorbs
more than half of all of the blood given in injury care in a
trauma center [8]. In the USA and Canada, 1200 hospitals
are certified by the American College of Surgeons as level 1,
2, or 3 trauma centers. A question in their certification is
whether they possess a plan for supporting massive blood
transfusion, but in only a handful of the largest centers is such
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a plan more than rudimentary. In England and North Wales,
only 23 out of 252 hospitals providing ambulance and
emergency services keep uncrossmatched group O blood in
their emergency rooms (Murphy M, personal communication).
In South Korea, the largest medical center in Seoul, serving a
population of 10,000,000 people, has a single trauma
resuscitation bay. The logistic limits and physiologic effects of
massive transfusion will only be seen in trauma care systems
that are set up to support it.
Transfusion in trauma care
In the USA blood is rarely used in prehospital care; this is for
a variety of reasons. (The exceptions involve trauma Go-
Teams and a small fraction of medical evacuation helicopters.)
Thus, essentially all blood is given in the hospital, and the
majority of transfusions will be ABO and Rh type specific. In
the review of blood use at University of Maryland Shock
Trauma Center [8] noted above, 5645 patients received
5219 units of RBCs, 5163 units of frozen plasma, 2782
equivalent units of platelets, and 62 units of cryoprecipitate.
In the acute injury cohort, only 9% received any blood
product, 8% received RBCs, 5% received plasma, and 3%
received platelets. Of all of the RBCs, 62% were given in the
first day. Of all units 11% were given during the first hour as
uncrossmatched group O RBCs. Using blood products in
this way was not associated with any obvious direct adverse
effects and was associated with a period of overall historically
low death rates for the Center. This experience echoes
American experience with the use of uncrossmatched group
O blood in Vietnam, which was associated with no deaths
from transfusion reactions [12]. However, blood bankers tend
to be uncomfortable with the use of uncrossmatched group
O blood, and this remains a point of debate in the speciality
[13]. Current guidelines in the UK on the use of blood
products highlight concerns over allergic reactions and
anaphylaxis, and transfusion-related lung injury [14].
Transfusion strategies
The starting place for any reasonable transfusion strategy is
to determine who needs blood. This point can be less
obvious in practice than it appears in theory. In the most
advanced trauma centers, imaging techniques such as whole
body computed tomography scanning (now achievable in
13 s) and focused abdominal sonography for trauma allow more
accurate early diagnosis. Early use of imaging techniques is
supported by the recognition that there appears to be no
increase in mortality associated with a short-term withholding
of fluids during a diagnostic phase in trauma patients whose
blood pressure is low but compatible with tissue perfusion
[15]. Thus, patients who present in a state of mild shock can
rapidly be classified into those who are likely to progress for
injury-related reasons and those who can probably be
stabilized with more limited measures.
Patients who are bleeding massively or whose blood
pressure is not compatible with observation can be given
crystalloid fluids and uncrossmatched group O RBCs as
soon as these are available, along with active physical
measures and surgical attempts to stop the bleeding.
However, massive crystalloid infusion induces early coagulo-
pathy [16]. Even with the use of RBCs early in resuscitation,
after transfusion of 6–12 units coagulation factors decrease
to the point at which the prothrombin time and activated
partial thromboplastin time are greater than 1.5 times normal,
and the likelihood of coagulopathy is significantly increased.
After 10–30 units of RBCs have been transfused platelet
counts typically fall to below 50,000/µl. The inability of
conventional laboratory testing to support decision making in
rapidly evolving massive injury situations is notorious. Point-
of-care monitoring for oxygen saturation and electro-
cardiographic changes is now routine in critical care and is
recommended by some [17] to guide transfusion. Point-of-
care laboratory evaluation of coagulopathy is also available.
Bedside devices can measure the prothrombin time
expressed as the percentage activity of a reference plasma.
However, this modality is not in widespread use. Trauma
clinicians generally acknowledge that coagulopathy is already
established by the time that laboratory testing is abnormal,
and that rescue correction is far more difficult that prevention.
Patient-to-patient variation in loss of coagulation activity is
high, but one can use the above information to outline a
massive transfusion protocol that supports timely assessment
and delivery of blood components in a manner that is
designed to prevent rather than ‘catch up’ with coagulopathy
[18]. The utility of massive transfusion protocols is unproven,
but they do provide some assurance that coagulation issues
are being addressed as care progresses.
Trauma-associated coagulopathy
Coagulopathy is an inevitable consequence of massive
bleeding. The coagulopathy of trauma appears to be the sum of
the effects of hypothermia, acidosis, and clotting element
consumption, loss, and dilution. Hypothermia acts pre-
dominantly on platelet activation and adhesion [19] but it also
slows the metabolic rates of the coagulation factor enzymes.
Acidosis predominantly affects activities of the enzyme
complexes on lipid surfaces [20]. Embolization of brain
substance, marrow fat, amniotic fluid, and other strong thrombo-
plastins causes disseminated intravascular coagulation, with
consumption of coagulation factors [21]. Extensive soft tissue
trauma with multiple disruptions of endothelial surfaces has a
similar effect. The direct loss of clotting factors through
hemorrhage rapidly reduces the body’s small normal stores of
10 g of fibrinogen and 15 ml of platelets. Resuscitiation, even
with blood components, causes further dilution [22].
The effect of hypothermia on the coagulopathy of trauma is
now well accepted, and surgical and critical care procedures
to limit hypothermia – blood, fluid, and body warming
techniques and limiting surgical exposure – are all routine [7].
Their importance cannot be overstressed [23].S12
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The contribution of acidosis is also well recognized but more
difficult to control because ancillary interventions are few.
Blood products, especially RBCs, contribute a small acid
load that can be multiplied across many units. The perception
that older RBC units create addition risk in trauma
resuscitation may be related in part to their greater acid load.
In addition, their greater oxygen affinity, reduced ability to
secrete ATP, and reduced deformability secondary to
membrane loss may all contribute to reduced oxygen delivery
to tissue with secondary acid production [24].
Identifying and treating infection is also critical. Fever can
worsen acidosis. Infectious inflammation can increase the
consumption of coagulation factors.
Finally, drugs and colloids can affect the coagulation system.
Many elderly people take one or more anticoagulant drugs
chronically. Dextrans and hydroxyethyl starch used in pre-
hospital resuscitation can also affect platelet function [25].
Timing
Once hemorrhage has been controlled and hemodynamic
stability achieved, the potential benefit of using additional
blood products must be weighed against their potential
toxicity. Spahn [17] recommended that the transfusion trigger
for RBCs be reduced to 6 g/dl but also recommended that
monitoring be conducted with electrocardiograms for ST-
segment depressions and transesophageal echocardio-
graphy for cardiac wall motion abnormalities. This transfusion
trigger is lower than is usually recommended [26]. These
recommendations will stress a busy trauma center, and their
ability to prevent untoward effects must be demonstrated.
Costs of blood products
All blood products in the USA and Europe come from
voluntary nonremunerated donors, and so the blood is
technically free. However, the costs of collection are
recovered, and these costs include the whole spectrum of
blood-banking operations: donor recruitment and counselling,
phlebotomy equipment and materials, phlebotomy personnel,
the leuko-reduction filters and other manufacturing parts and
labor, operating costs and amortization for buildings and
refrigerators, testing, and transportation. The end result is that
1 unit of RBCs typically costs a hospital about US$150. The
hospital’s own costs for storage, typing and crossmatching,
and issuing a unit from the blood bank and the nursing costs
of identifying and hanging the unit add at least another
US$100 to the cost. If operating room time is consumed
while waiting for blood, then costs can rise sharply. Hospital
costs for other common blood products are about US$450
dollars for an apheresis ‘6-unit pack’ of platelets, and US$40
for a unit of plasma.
Spread across an institution with much activity such as a
university medical center, the cost of 30,000 units of RBCs,
8000 apheresis units of platelets, and 15,000 units of plasma
is about US$9 million a year (costs calculated for the
University of Maryland, unpublished data). The cost of hiring
40 blood bank workers and buying reagents and equipment
to permit testing and issuing around the clock adds another
US$3 million. This represents about 2–3% of the total cost of
running a large medical center. The cost of pharmaceuticals
is about 10 times greater.
In a trauma center, 9% of patients receive all of the blood
products [8]. The procurement cost for the median dose of
11 units of RBCs, 11 units of plasma, and 6 units of platelets
for a typical transfused trauma patient was found to be
US$2540. The 3% of trauma patients who were massively
transfused – that is, who received more than 10 units of
RBCs – received a mean of 25 units of RBCs, 24 units of
plasma, and 16 units of platelets, with a procurement cost of
US$5060. The fraction of the total cost of care accounted for
by the cost of blood products will be very different for the
patient who receives 50 units of RBCs in 4 hours before
dying in the operating room than for a similar patient who
survives to spend 40 days in the trauma center and recovers.
However, the cost of treating both is part of the price of
saving one.
Areas of controversy
Blood bankers versus the trauma team
Transfusion medicine is a young specialty [27]. Its members
are largely drawn from among clinical pathologists and its
concerns are focused on how to keep blood banks and trans-
fusion services staffed, licensed, accredited, and supplied.
Blood bankers are not usually clinicians. In this environment,
standard operating procedures and evidence-based clinical
guidelines play a substantial role. The majority of the evidence
and guidelines released during the past two decades has
suggested that less blood is better, but the caveat that these
guidelines generally apply to hemodynamically stable patients
is often overlooked [28], and the clash between the action
driven trauma surgeon and the cautious blood banker
appears predestined. Critical points of concern are the rapid
availability of uncrossmatched group O blood and thawed
plasma.
On the other hand, trauma center leaders must understand
that transfusion services can lose their licenses if individual
blood units are handled in unaccountable ways. Also, O
negative blood is in limited supply (6% of the population) and
is needed for babies and O negative patients.
Can massive transfusion be orderly?
The most seriously injured patients often arrive in the emer-
gency room in profound shock. Controlling hemorrhage and
restoring perfusion are the goals, but sometimes the nature of
wounds means that hemorrhage cannot be controlled
immediately. Under these circumstances, obtaining vascular
access and beginning resuscitation are immediate needs.
Initial objectives of this early phase of resuscitation areS13
obtaining minimal tissue perfusion while maintaining hemo-
globin concentrations compatible with short-term survival and
organ preservation. Administration of crystalloid fluid and
uncrossmatched group O RBCs can be life-saving. The
profound hypovolemia associated with such shock, and
continued fluid administration and loss lead to rapid washout
of coagulation factors in excess of amounts predicted by
isovolemic exchange equations [29].
In the second phase of these patients’ care, surgical teams
obtain high volume vascular access and give sufficient RBCs
and thawed plasma to support surgical exploration and
treatment of wounds that cannot be clamped off primarily. In
some patients, this phase lasts for hours, leading to truly
massive transfusions of many tens of units of RBCs, along
with plasma and platelets to limit dilutional coagulopathy.
There are no evidence-based guidelines on how such
massive transfusion should be carried out. However, retro-
spective evidence suggests that patients receiving relatively
more plasma and platelets during this phase of treatment do
better [7,29]. Blood products given at a 1:1:1 ratio of RBCs
to plasma units to platelet units yield plasma coagulation
factor and platelet concentrations close to values associated
with best outcomes and have the advantage of ease of
bedside management. Formalizing this suggestion as a
protocol would allow it to be tested.
Can we use less blood?
The utility of blood in the prehospital phase of care is largely
unknown. Examples of its successful application largely come
from military experience in which blood was used in Casualty
Clearing Stations (World War I) or Battalion Aid Stations
(World War II), where it was used in conjunction with
bandaging and preliminary surgical care of varying
sophistication [30,31]. In good hands it probably saved many
lives, especially when evacuation was delayed. The desire to
protect and centralize medical assets since that time led to an
emphasis on rapid evacuation, which in turn has left a video
record, from Vietnam at least, of casualties being loaded onto
helicopters with spouting arterial hemorrhage. Descriptions of
prehospital blood use are now largely anecdotal, but situations
in which benefit might reasonably be expected are uncommon.
The use of blood in the resuscitation and initial hemorrhage
control phase of the care of severely injured trauma patients
is justified by the fact that these patients will die very quickly
without some form of both volume and oxygen carrying
capacity. Blood is the only widely available and clinically
established solution. Clinical demonstrations that some
trauma patients can be sustained with polymerized hemo-
globin solutions are interesting, but the published small and
uncontrolled series give no sense of the relative benefits of
the alleged reduced inflammatory potential claimed for the
polyhemoglobin products compared with the clear problem of
markedly increased hemodilution leading to coagulopathy
with these colloid solutions [32,33].
As noted previously, Spahn [17] suggested that blood
products can be safely withheld to a hemoglobin concen-
tration of 6 g/dl in critically ill patients in the poststabilization
phase, using electrocardiographic and echocardiographic
indicators of physiologic need for transfusion. Whether this
is safe or effective in reducing post-transfusion
complications remains to be demonstrated, but there is a
move toward more conservative use of transfusion and an
acceptance that lower transfusion trigger points may be
appropriate [26].
As noted above, the extent of hemorrhage, and therefore of
potential need for blood replacement, is a function of the
degree of vascular disruption, blood pressure at the anatomic
site of the injury, and time between injury and definitive care.
First aid techniques, such as tourniquets, that decrease blood
flow from a wound and community commitment to rapid
medical evacuation via helicopters will deliver patients to
definitive care with relatively less blood loss. Attempts to
provide interim care in the field, such as administration of
fluids, prolongs time to definitive care and delivers patients
with less of their own blood in them.
Advanced hemorrhage control devices suitable for field use,
such as the dry fibrin sealant dressing (DFSD), can seal large
vessel injury within 1 min of application [34]. These would
appear to have potential to reduce blood loss and, therefore,
to reduce need for blood transfusion. The DFSD is no longer
in production (vide ifra), but plans are underway to start
development again.
Stimulation of coagulation at the site of injury with
recombinant factor VIIa has now been demonstrated in a
number of case reports, clinical series, and small randomized
trials [35-37]. Additional randomized trials are still needed,
but clinical evidence is accumulating that the use of recom-
binant factor VIIa, especially in the massively transfused, can
dramatically limit further blood loss and need for ongoing
transfusions. Cost issues are being addressed with the
development of more active congeners and more efficient
methods of production.
Blood product shortages
Short-term blood shortages occur when weather, holidays,
power outages, and disease outbreaks keep donors away or
limit established patterns of blood product distribution. Such
short-term fluctuations in the availability of donors or products
most commonly affect the supply of platelets, but RBC
shortages can also occur because regional reserves are
frequently low. At the national level, the recent decision of the
American Red Cross not to produce the DFSD was driven in
part by the overall limits on the national supply of plasma and
the prior commitment of that supply to make albumin and
intravenous gammaglobulin. In contrast to popular belief and
instinct, however, blood shortages are rare to nonexistent
after natural or other disasters [38].
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Conclusion
Our immediate future on this planet involves more people,
more vehicles, and more weapons. Good trauma care will
demand the best access to medicine, including transfusion. A
better understanding of the physiologic bases and
consequences of hemorrhage, transfusion, and coagulopathy
are critical to the development of better ways to cope with all
three. New tools and methods must also demonstrate efficacy
and safety. In addition, across the spectrum of advanced
trauma care, the care givers must communicate effectively.
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